Arvinas - ARVN Stock Forecast, Price & News

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

18 equities research analysts have issued 1 year target prices for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they predict the company's stock price to reach $68.75 in the next twelve months. This suggests a possible upside of 133.4% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $34.21 at the beginning of the year. Since then, ARVN stock has decreased by 13.9% and is now trading at $29.46.
View the best growth stocks for 2023 here.

Arvinas saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 5,070,000 shares, an increase of 6.5% from the February 13th total of 4,760,000 shares. Based on an average daily volume of 491,100 shares, the days-to-cover ratio is currently 10.3 days. Currently, 11.1% of the shares of the company are sold short.
View Arvinas' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) announced its earnings results on Thursday, February, 23rd. The company reported ($1.56) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.46. The firm had revenue of $38 million for the quarter, compared to analysts' expectations of $35.32 million. Arvinas had a negative net margin of 228.19% and a negative trailing twelve-month return on equity of 43.79%. The business's revenue was up 32.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.00) earnings per share.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), Harbor Disruptive Innovation ETF (INNO) and BlackRock Future Health ETF (BMED).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (9.30%), Price T Rowe Associates Inc. MD (4.45%), JPMorgan Chase & Co. (3.70%), ArrowMark Colorado Holdings LLC (2.25%), T. Rowe Price Investment Management Inc. (2.17%) and American Century Companies Inc. (1.74%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $29.46.

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.57 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.32) on an earnings per share basis.

The company employs 280 workers across the globe.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.